BCL2 and cancer: This feature, together with the concurrent downregulation of other anti-apoptotic molecules belonging to both IAP and Bcl-2 families and the upregulation of pro-apoptotic proteins, induced a greater apoptotic response in TRAIL-R2-positive cancer cell models, which resulted in an enhanced anticancer effect when compared with individual agents.